Aldo Leone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aldo Leone has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Fabrizio Pane
Department of Clinical Medicine and Surgery, Hematology Unit Federico II University Medical School Naples Italy
3 shared publications - Roberta Della Pepa
Department of Clinical Medicine and Surgery University Federico II Naples Italy
3 shared publications Simona Avilia
Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
3 shared publications- Alessandra Picardi
Stem Cell Transplant Program AORN Cardarelli, Naples, Italy and Biomedicine and Prevention Department of Tor Vergata University, Rome, Italy
1 shared publication - Bernardo Rossini
Hematology and Cell Therapy Unit, IRCCS Istituto Tumori “Giovanni Paolo II” Bari, 70124 Bari, Italy
1 shared publication Bianca Serio
Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy
1 shared publication
Latest Publications
- Open Access
- 26 March 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (4) , 206
Recurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series
Bispecific antibodies targeting B-cell maturation antigen, BCMA (teclistamab) or G protein–coupled receptor, class C, group 5 member D, GPRC5D (talquetamab) are effective treatments for relapsed or refractory multiple myeloma. Their main early toxicity is cytokine release syndrome (CRS), usually transient and limited to initial cycles. We report five patients with relapsed or refractory multiple myeloma who received bispecific antibodies (n = 1 teclistamab; n = 4 talquetamab) who developed a pattern of recurrent, cyclic CRS beyond the initial step-up phase. All patients achieved at least a partial hematologic response, with complete or stringent complete remission in most cases. Recurrent febrile episodes occurred at regular intervals after drug administration, despite repeatedly negative infectious workups. CRS episodes were generally grade 1–2 and resolved with tocilizumab, with or without corticosteroids. In one patient treated with teclistamab, recurrent CRS contributed to treatment discontinuation due to renal complications. Attenuation of CRS severity over time was observed in some patients, allowing treatment continuation with tailored premedication strategies. This case series describes an unusual pattern of recurrent CRS occurring during bispecific antibody therapy for multiple myeloma. Recognition of this phenomenon is essential to avoid misdiagnosis as infection and unnecessary antimicrobial use. Systematic reporting of such real-world adverse events may help refine supportive care strategies.
- 26 March 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (4) , 206
Open AccessRecurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series
Bispecific antibodies targeting B-cell maturation antigen, BCMA (teclistamab) or G protein–coupled receptor, class C, group 5 member D, GPRC5D (talquetamab) are effective treatments for relapsed or refractory multiple myeloma. Their main early toxicity is cytokine release syndrome (CRS), usually transient and limited to initial cycles. We report five patients with relapsed or refractory multiple myeloma who received bispecific antibodies (n = 1 teclistamab; n = 4 talquetamab) who developed a pattern of recurrent, cyclic CRS beyond the initial step-up phase. All patients achieved at least a partial hematologic response, with complete or stringent complete remission in most cases. Recurrent febrile episodes occurred at regular intervals after drug administration, despite repeatedly negative infectious workups. CRS episodes were generally grade 1–2 and resolved with tocilizumab, with or without corticosteroids. In one patient treated with teclistamab, recurrent CRS contributed to treatment discontinuation due to renal complications. Attenuation of CRS severity over time was observed in some patients, allowing treatment continuation with tailored premedication strategies. This case series describes an unusual pattern of recurrent CRS occurring during bispecific antibody therapy for multiple myeloma. Recognition of this phenomenon is essential to avoid misdiagnosis as infection and unnecessary antimicrobial use. Systematic reporting of such real-world adverse events may help refine supportive care strategies.
- Open Access
- 5 September 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (10) , 5371-5378
Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study
Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) is a highly effective induction therapy for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplantation (ASCT). However, its impact on stem cell mobilization requires a critical evaluation. This study examines the effects of Dara-VTD on stem cell mobilization and collection outcomes. A multicenter retrospective study included 81 consecutive NDMM patients treated with Dara-VTD (from November 2021 to June 2023). Data on stem cell mobilization and collection were compared with 93 historical VTD patients. Mobilization regimens included cyclophosphamide (CTX), vinorelbine + CTX, and chemotherapy-free approaches, with plerixafor used as rescue therapy. Mobilization success was evaluated by CD34 + cell yield, additional agent use, and leukapheresis sessions required. The median CD34 + yield in the Dara-VTD group was 5.1 million cells/kg, with 96.3% of patients achieving > 2 × 10^6 cells/kg of body weight. Plerixafor use was significantly higher in the Dara-VTD group (56.2%) compared to VTD (4.3%), and CTX-based regimens showed superior mobilization efficacy ( p = 0.01). Engraftment was faster in the Dara-VTD group, with median neutrophil and platelet recovery at 11 and 13 days, compared to 12 and 17 days in the VTD group ( p < 0.05). Dara-VTD maintains the feasibility of ASCT, with comparable stem cell mobilization and collection outcomes to VTD. Mobilization success is influenced by individualized strategies, with CTX and plerixafor playing key roles in optimizing stem cell yield. Despite the challenges posed by daratumumab, stem cell mobilization remains effective, and Dara-VTD does not compromise the transplant process.
- 5 September 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (10) , 5371-5378
Open AccessImpact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study
Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) is a highly effective induction therapy for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplantation (ASCT). However, its impact on stem cell mobilization requires a critical evaluation. This study examines the effects of Dara-VTD on stem cell mobilization and collection outcomes. A multicenter retrospective study included 81 consecutive NDMM patients treated with Dara-VTD (from November 2021 to June 2023). Data on stem cell mobilization and collection were compared with 93 historical VTD patients. Mobilization regimens included cyclophosphamide (CTX), vinorelbine + CTX, and chemotherapy-free approaches, with plerixafor used as rescue therapy. Mobilization success was evaluated by CD34 + cell yield, additional agent use, and leukapheresis sessions required. The median CD34 + yield in the Dara-VTD group was 5.1 million cells/kg, with 96.3% of patients achieving > 2 × 10^6 cells/kg of body weight. Plerixafor use was significantly higher in the Dara-VTD group (56.2%) compared to VTD (4.3%), and CTX-based regimens showed superior mobilization efficacy ( p = 0.01). Engraftment was faster in the Dara-VTD group, with median neutrophil and platelet recovery at 11 and 13 days, compared to 12 and 17 days in the VTD group ( p < 0.05). Dara-VTD maintains the feasibility of ASCT, with comparable stem cell mobilization and collection outcomes to VTD. Mobilization success is influenced by individualized strategies, with CTX and plerixafor playing key roles in optimizing stem cell yield. Despite the challenges posed by daratumumab, stem cell mobilization remains effective, and Dara-VTD does not compromise the transplant process.
- Open Access
- 19 May 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (2) , 196-197
Isatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma
- 19 May 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (2) , 196-197
Open AccessIsatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma